Hereditary Transthyretin Cardiac Amyloidosis With the p.V142I Variant: Mechanistic Insights and Diagnostic Challenges
Circulation: Heart Failure · 2025
DOI: 10.1161/circheartfailure.124.012469 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Circulation: Heart Failure, 2025. Verfasst von Simon Vanhentenrijk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Kaufman Center for Heart Failure Treatment and Recovery, Heart Vascular and Thoracic Institute, Cleveland Clinic, OH (S.V., W.H.W.T.). Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Prealbumin, Cardiomyopathies, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
The most common form of hereditary transthyretin cardiac amyloidosis (hATTR-CA) in the United States and the United Kingdom is the p.V142I variant. About 3% to 4% of patients with African ancestry carry this genetic predisposition to develop signs and symptoms of hATTR-CA. Nevertheless, clinical manifestations of hATTR-CA appear only late in the fifth and sixth decades of life, despite its clear genetic background. Imbalances in native protein-stabilizing and elementary breakdown cellular mechanisms are postulated as potential causes for affecting transthyretin structural integrity and myocardial fibril deposition. Noncoding variants, epigenetic and environmental factors, as well as gut microbiome derangements may serve as disease-modifying factors that feature detrimental amyloidogenic organ involvement and impact disease severity. Organ amyloid deposition varies widely among different carriers of a genetic transthyretin variant. The genotype-phenotype interdependence causes unpredictable phenotypic penetrance that results in a variety of signs and symptoms and patient outcomes. Cardiovascular biomarkers and multimodality imaging may identify initial amyloidogenic organ involvement. These early clinical clues through the course of hATTR-CA offer a window of opportunity for early treatment onset to cease disease progression and alter prognosis. Identifying at-risk patients requires information on the genetic background of probands and their relatives. Initiatives to reveal asymptomatic gene carriers early in the disease should be encouraged, as it necessitates stringent patient follow-up and immediate treatment onset to reduce the burden of heart failure hospitalization and mortality in hATTR-CA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kaufman Center for Heart Failure Treatment and Recovery, Heart Vascular and Thoracic Institute, Cleveland Clinic, OH (S.V., W.H.W.T.).
- Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (J.L.G.).
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, OH (S.N.A., W.H.W.T.).
ORCID-Profile: Simon Vanhentenrijk, Justin L Grodin, Silvio Nunes Augusto
Förderung
- NHLBI NIH HHS
Zitieren
APA
Vanhentenrijk, S., Grodin, J. L., Augusto, S. N., & Tang, W. H. W. (2025). Hereditary Transthyretin Cardiac Amyloidosis With the p.V142I Variant: Mechanistic Insights and Diagnostic Challenges. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.124.012469
Vancouver
Vanhentenrijk S, Grodin JL, Augusto SN, Tang WHW. Hereditary Transthyretin Cardiac Amyloidosis With the p.V142I Variant: Mechanistic Insights and Diagnostic Challenges. Circulation: Heart Failure. 2025. doi:10.1161/circheartfailure.124.012469
BibTeX
@article{Vanhentenrijk2025,
author = {Vanhentenrijk, Simon and Grodin, Justin L and Augusto, Silvio Nunes and Tang, W H Wilson},
title = {Hereditary Transthyretin Cardiac Amyloidosis With the p.V142I Variant: Mechanistic Insights and Diagnostic Challenges},
journal = {Circulation: Heart Failure},
year = {2025},
doi = {10.1161/circheartfailure.124.012469}
}
EUVIMED